Your Search Returned 5 tagged news reports
South San Francisco-based Genentech on sales of the skin cancer drug Erivedge, to help pay for research and development. The Food and Drug Administration approved Erivedge in January for basal cell carcinoma. Curis will get exclusive worldwide rights
rallied 17 percent to $2.43 after jumping as much as 18 percent, the most intraday since May 2009. The maker of rechargeable batteries responded to the 14 allegations in a March 30 report published by Variant View Research and said the article "
Find Executives Genentech Inc. could dump a potential ovarian cancer drug under development with partner Curis Inc. Phase II trial of GDC-0449 , which is a potential maintenance therapy for ovarian cancer patients in their second or third complete
Mass. — Drug developer Curis Inc. said Friday it will receive a $8 million payment from partner Debiopharm SA after that company received French regulatory approval to begin human studies on a potential cancer treatment. Curis licenses small molecule
Cancer drug developer Curis Inc. said Friday it is offering just under 6.5 million units of stock and warrants for about $16.3 million...Each unit consists of one common share and a warrant to buy a quarter of a share. The offering priced at a 15